Crossmark

Agents of change: establishing quality improvement collaboratives to improve adherence to Australian clinical guidelines for dementia care

Crossref DOI link: https://doi.org/10.1186/s13012-018-0820-z

Published Online: 2018-09-24

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cations, Monica https://orcid.org/0000-0002-9262-0463
Crotty, Maria

Fitzgerald, Janna Anneke

Kurrle, Susan

Cameron, Ian D.

Whitehead, Craig

Thompson, Jane

Kaambwa, Billingsley

Hayes, Kate

de la Perrelle, Lenore

Radisic, Gorjana

Laver, Kate E.
Funding

Funding for this research was provided by:

Australian National Health and Medical Research Council (1135667)

Australian National Health and Medical Research Council Cognitive Decline Partnership Centre (CDPC1327)
License Information

Text and Data Mining valid from 2018-09-24
More Information

Article History

Received: 16 August 2018

Accepted: 12 September 2018

First Online: 24 September 2018

Ethics approval and consent to participate

: Ethical approval for this study has been granted by the Southern Adelaide Clinical Human Research Ethics Committee (HREC/17/SAC/88).

: No person’s individual data are contained in this manuscript.

: Monica Cations has been employed in the past 5 years to assist with data collection for Alzheimer’s disease drug trials funded by Janssen and Merck. Maria Crotty receives funding from Novartis for trials of hip fracture involving treatments for sarcopenia. Ian Cameron has received funding for lecturing from Amgen. AF, SK, CW, JT, BK, KH, GR, LDLP, and KL have no competing interests to declare.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.